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 2 
Abstract 25 
Infection by Shigella spp. is a common cause of dysentery in Southeast Asia. Antimicrobials 26 
are thought to be beneficial for treatment, however antimicrobial resistance in Shigella spp. is 27 
becoming widespread. We aimed to assess the frequency and mechanisms associated with 28 
decreased susceptibility to azithromycin in Southeast Asian Shigella isolates and use these 29 
data to assess appropriate susceptibility breakpoints. Shigella isolated in Vietnam and Laos 30 
were screened for susceptibility against azithromycin (15µg) by disc diffusion and minimum 31 
inhibitory concentration (MIC). Phenotypic resistance was confirmed by PCR amplification 32 
of macrolide resistance loci. We compared the genetic relationships and plasmid contents of 33 
azithromycin resistant S. sonnei using whole genome sequences. From 475 available Shigella 34 
spp. isolated in Vietnam and Laos between 1994 and 2012, 6/181 S. flexneri (3.3%, 35 
MIC≥16g/L) and 16/294 S. sonnei (5.4%, MIC≥32g/L) were phenotypically resistant to 36 
azithromycin. PCR amplification confirmed a resistance mechanism in 22/475 (4.6%) isolates 37 
(19 mphA and 3 ermB). Susceptibility data demonstrated the acceptability of S. flexneri 38 
(MIC≥16g/L, zone≤15mm) and S. sonnei (MIC≥32g/L, zone≤11mm) breakpoints with <3% 39 
discrepancy. Phylogenetic analysis demonstrated that decreased susceptibility has arisen 40 
sporadically in Vietnamese S. sonnei on at least seven occasions between 2000 and 2009, but 41 
failed to become established. While the proposed susceptibility breakpoints may allow better 42 
recognition of resistant isolates, additional studies are required to assess the impact on clinical 43 
outcome. The potential emergence of azithromycin resistance highlights the need for 44 
alternative management options for Shigella infections in endemic countries.45 
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 3 
Introduction 46 
Organisms of the bacterial genus Shigella are a common cause of moderate to severe diarrhea 47 
and dysentery in children attending day-care facilities, those living in resource-limited 48 
settings, and travellers to such areas (1-5). In many low to middle-income countries (LMICs), 49 
such as Vietnam, endemic shigellosis is now predominantly caused by Shigella sonnei. 50 
Sustained antimicrobial pressure in LMICs has led to the emergence of resistance to the 51 
antimicrobials used for treating shigellosis (6,7). In Southeast Asia, antimicrobial resistance 52 
(AMR) in the Shigellae is largely being driven by the expansion of a specific S. sonnei 53 
lineage, which is known as Global III (8).  54 
 55 
AMR within the genus Shigella is a problem for clinical management (9,10). The treatment of 56 
Shigella infections with antimicrobials is recommended by most clinical guidelines, 57 
predominantly to reduce the risk of onward transmission and disease complications. The 58 
WHO currently recommends ciprofloxacin as first-line treatment, with pivmecillinam, 59 
ceftriaxone, and azithromycin as alternative options. However, Shigella spp. are adept at 60 
acquiring AMR genes and plasmids, and reports of multi-drug resistant (MDR) lineages or 61 
isolates with reduced susceptibility to fluoroquinolones and third-generation cephalosporins 62 
are increasing globally (11,12)  63 
 64 
Some recent recommendations have advocated the oral azalide antimicrobial azithromycin as 65 
an alternative treatment for shigellosis, particularly infections caused by MDR organisms or 66 
when fluoroquinolones are inappropriate (9,13). Clinical evidence for the efficacy of 67 
azithromycin in treating shigellosis is limited (14,15), and there are presently no suitable 68 
clinically derived susceptibility breakpoints to facilitate the laboratory identification of 69 
Shigella spp. exhibiting azithromycin non-susceptibility. Recently updated CLSI guidelines 70 
suggest epidemiological cut-off values (ECVs) of Minimum Inhibitory Concentrations (MIC) 71 
≥16mg/L and MIC≥32mg/L to categories non-wild type S. flexneri and S. sonnei, respectively 72 
(16). Data supporting these guidelines are limited, principally originating from reports of an 73 
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 4 
international outbreak of S. flexneri serotype 3a among men who have sex with men (MSM) 74 
(17-19). Here, we aimed to assess the frequency and mechanisms of Shigella spp. isolates 75 
with decreased susceptibility against azithromycin in Southeast Asia, a setting where 76 
fluoroquinolone and third-generation cephalosporin resistance has become common. 77 
Additionally, using a large dataset from Vietnam and Laos spanning 18 years, we aimed to 78 
calculate suitable breakpoints for assessing Shigella susceptibility against azithromycin. 79 
 80 
Materials and methods 81 
Ethics statement 82 
Bacterial isolates and data for this investigation originated from clinical studies approved by 83 
the scientific and ethical committees of the Hospital for Tropical Diseases in HCMC, all other 84 
participating hospitals, and the Oxford Tropical Research Ethics Committee (OXTREC) in 85 
the United Kingdom. The study also included the characterization of bacterial isolates 86 
submitted for routine diagnostic purposes. Study participants or parents of young participants 87 
were required to provide written informed consent for the collection of samples and 88 
subsequent analyses, except when samples were collected as part of routine care. 89 
 90 
Study sites 91 
The majority of fecal specimens from which Shigella spp. were isolated were collected in a 92 
series of pediatric studies performed in Vietnam between 1994 and 2012, as previously 93 
described (6). Briefly, children presenting with either diarrhea or dysentery were recruited 94 
into observational studies (6, 20, 21), or treatment trials (22, 23) performed at the Hospital for 95 
Tropical Diseases (HTD), Children’s Hospital 1, or Children’s Hospital 2 in Ho Chi Minh 96 
City, Vietnam. Additional microbiology isolates collected for routine diagnostic purposes 97 
were also included from Huế Central Hospital in Huế and Khanh Hoa General Hospital in 98 
Nha Trang, Vietnam, and Mahosot Hospital in Vientiane, Laos. 99 
 100 
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 5 
Microbiology methods 101 
Fecal samples were collected and processed as previously described using standard 102 
microbiological methods (6, 24). Briefly, non-lactose fermenting colonies grown on 103 
MacConkey and/or Xylose Lysine Desoxycholate (XLD) agar (Oxoid), were identified 104 
biochemically (API20E; biomerieux, Vietnam) and by slide agglutination with polyvalent 105 
somatic (O) and monovalent serotype-specific grouping antisera (Denka Seiken, Japan in 106 
Vietnam & Pro-Lab Diagnostics, UK in Laos). Azithromycin susceptibility testing against 107 
was performed at a single laboratory in Vietnam using Kirby-Bauer disc diffusion method 108 
(15µg disc) and by MIC antimicrobial gradient diffusion (Etest, AB Biodisk, Sweden on both 109 
on Mueller-Hinton agar (Oxoid).  110 
 111 
Molecular methods 112 
Genomic DNA was extracted from S. flexneri and S. sonnei isolates using the Wizard 113 
Genomic DNA Extraction Kit (Promega) following the manufacturers’ recommendations, 114 
with the quality and quantity assessed using the Quant-IT Kit (Invitrogen) prior to 115 
sequencing. PCR amplification for the detection of macrolide resistance genes (mphA/B, 116 
ermA/B/D, ereA/B, and mefA/B) was performed as previously described (25).  117 
 118 
In addition, we performed phylogenetic analysis of 247 existing S. sonnei genomes (global 119 
lineage III) and an additional 68 contemporary genomes of isolates collected during the same 120 
period (1995-2011) (6) (accession numbers available in Table S1). Briefly, raw Illumina reads 121 
were mapped against an S. sonnei reference genome (strain Ss046 chromosome, accession 122 
number NC_007382 and pINV B plasmid, accession number NC_00735) using BWA and 123 
SNPs were called using SAMtools (26, 27). Phylogenetic reconstruction was performed using 124 
multiple alignment of SNPs by maximum-likelihood based phylogenetic inference (RAxML, 125 
version 8.2.8) (28) with a GTR+GAMMA substitution model. Bootstrap support for the 126 
maximum-likelihood phylogeny was accessed by 1,000 pseudo-replicates. Phylogenetic tree 127 
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 6 
was displayed and annotated using iTOL (29), highlighting the presence/absence of macrolide 128 
resistance genes over the study period among terminal taxa. 129 
 130 
Plasmid isolation and sequencing 131 
Bacterial conjugation was performed as described previously by combining representative 132 
isolates carrying ermB (EG430), mphA (DE891) and E. coli J53 (sodium azide resistant) (30). 133 
E. coli transconjugants were selected on media containing sodium azide (100mg/L) and 134 
azithromycin (24mg/L). ErmB/mphA-containing plasmids were extracted using plasmid Midi 135 
kit (Qiagen) and sequenced using the MiSeq Illumina platform with 2x250bp pair-end reads. 136 
De novo assembly was performed using SPADES v3.6.2 and annotated using Prokka (v1.11) 137 
(31,32). ABACAS was used to map all the assembled contigs against a concatenated 138 
reference sequence containing S. sonnei Ss046 chromosome (NC_007382), virulence plasmid 139 
pSs046 (NC_007385.1) and three small plasmids commonly found in S. sonnei belonging to 140 
Global lineage III: spA  (NC_009345.1) spB (NC_009346.1), spC (NC_009347.1) (33). The 141 
unmapped assembled sequences were presumed to contain ermB/mphA-encoding plasmids 142 
and Incompatibility (Inc) groups were then determined using in silico PCR by mapping the 143 
primers described previously to these unmapped sequences using an in-house script at the 144 
Sanger Institute (34). The presence of the ermB/mphA plasmid was confirmed by BLASTN 145 
searching the plasmid sequences to the previously sequenced plasmids in Genbank and 146 
comparative analysis was performed and visualized using ACT (35).  147 
 148 
Statistical analysis 149 
Statistical analysis of Shigella spp. isolates was limited to S. flexneri and S. sonnei only, as 150 
insufficient numbers of other species were available (Table 1). For comparisons of 151 
proportions of non-susceptible isolates, intermediate and resistant isolates were grouped 152 
together and compared with the proportion of susceptible isolates using Fisher’s exact test. 153 
Comparison of MIC measurements from different time periods was performed by ANOVA 154 
and subsequent Dunn’s test with Bonferroni correction for multiple testing, with a threshold 155 
 o
n
 February 12, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://aac.asm
.org/
D
ow
nloaded from
 
 7 
of p<0.05 considered significant. To determine appropriate azithromycin breakpoints, MIC 156 
histograms were constructed and disc zone diameter breakpoints were selected using the 157 
modified error rate-bounding method of Metzler and De Haan, according to CLSI 158 
recommendations (36).  159 
Accession no(s). The sequence for plasmid pDE105 has been deposited in GenBank under 160 
accession no. MG569891. 161 
Results 162 
Decreased susceptibility to azithromycin in Shigella spp. in Southeast Asia 163 
Data from a total of 517 Shigella (198 S. flexneri, 308 S. sonnei, and 11 others) isolated 164 
between 1994 and 2012 in Vietnam (6 studies, 472 isolates) and Laos (45 isolates) (Table 1) 165 
were available for antimicrobial susceptibility analysis. In this collection of organisms, 166 
180/198 (91%) S. flexneri were defined as being MDR (resistant to ≥3 classes of 167 
antimicrobials), 3/196 (2%) were resistant to ceftriaxone, and 78/196 (40%) were resistant to 168 
nalidixic acid. In contrast, significantly fewer S. sonnei isolates were MDR (181/308, 59%; 169 
p<0.0001), while a greater proportion exhibited resistance to ceftriaxone (92/307, 30%; 170 
p<0.0001), and nalidixic acid (174/307, 69%; p=0.0003) (20).  171 
 172 
From the 517 Shigella isolates collected over the defied period, 479 were recovered and 173 
available for azithromycin susceptibility testing; 181/479 (37.8%) S. flexneri, 294/479 174 
(61.4%) S. sonnei, and 4/479 (0.8%) isolates belonging to other Shigella species (not 175 
considered further). The distributions of the azithromycin MICs against azithromycin of the 176 
475 Shigella isolates collected over the sampling period are shown in Figure 1. The combined 177 
MIC50 for azithromycin was 4mg/L (MIC90, 8mg/L); the S. sonnei isolates exhibited a higher 178 
range of MIC values (IQR, 4 to 8 mg/L) in comparison with the S. flexneri isolates (IQR, 2 to 179 
4mg/L). The proportion of S. flexneri isolates with an MIC≥16mg/L was 6/181 (3.3%, 180 
95%CI, 1.4 to 7.4), whereas the proportion of S. sonnei isolates with an MIC≥32mg/L was 181 
16/294 (5.4%, 3.2 to 8.9; p>0.05). 182 
 183 
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 8 
Genes conferring decreased susceptibility against azithromycin 184 
Isolates were screened by PCR amplification for the macrolide resistance genes ermA/B/C, 185 
mphA/B, ereA/B, and msrA and mefA, which encode antimicrobial efflux mechanisms. 186 
Nucleic acid extractions from 19/475 (4.0%) isolates generated an amplicon for mphA; 14 S. 187 
sonnei and 5 S. flexneri (Table 2). The majority of these organisms had azithromycin MICs of 188 
≥32mg/L with a corresponding zone of inhibition of ≤14mm; three S. flexneri isolates had 189 
azithromycin MICs of 16mg/L and zone sizes of 11 and 12mm (2 isolates) to a 15µg 190 
azithromycin disc. A further three organisms produced ermB amplicons (3/475, 0.6%). The 191 
only ermB amplification positive S. flexneri isolate had a lower MIC (16mg/L) and larger 192 
inhibition zone size (12mm) in comparison to the two S. sonnei isolates (MIC 32mg/L, zone 193 
size 9mm). These data suggest that S. sonnei and S. flexneri exhibit different distribution of 194 
MICs when harboring the mphA and/or ermB genes.  195 
 196 
Determining disc susceptibility breakpoints for azithromycin 197 
The CLSI recently provided ECV for determining azithromycin resistance in S. flexneri (disc 198 
diffusion and MIC) and S. sonnei (MIC only) (16). While ECVs are not generally 199 
recommended for determining clinical susceptibility breakpoints, we used these same criteria 200 
in our dataset, given that clinical data on azithromycin usage was not available. We aimed to 201 
determine whether the CLSI cut-off values could be used to determine suitable disc diffusion 202 
breakpoints for S. sonnei. Azithromycin disc inhibition zone sizes were available for 181 S. 203 
flexneri and 294 S. sonnei isolates. A regression analysis for determining the suitability of 204 
MIC data to extrapolate disc diffusion breakpoints demonstrated a significant correlation 205 
between MIC and disc diffusion zone size for S. flexneri (rho, -0.845; p<0.0001; Spearman) 206 
and to a lesser extent for S. sonnei (rho, -0.649; p<0.001). 207 
 208 
For S. flexneri, a breakpoint zone size of ≤15mm exhibited good discrimination against a 209 
15µg azithromycin disc to identify non-susceptible isolates. Using an error rate-bounding 210 
method, a 3% major error rate was found, and with a ≤15mm breakpoint there were no very 211 
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 9 
major or minor errors when compared an MIC of ≤8mg/L (Table 3, Figure 2), thereby 212 
fulfilling CLSI recommendations (36). In contrast, while the ECV MIC threshold of ≥32mg/L 213 
appeared to define non-susceptible S. sonnei, no clear demarcation in disc diffusion zone size 214 
measurements was observed (Figure 2). The largest azithromycin zone of inhibition in the S. 215 
sonnei isolates with a known azithromycin resistance mechanism was 9mm. We aimed to 216 
identify the largest zone size concordant with a permissible CLSI error rate. We determined 217 
that a cut-off of ≤11mm resulted in an acceptable discrepancy rate (Table 3), whereas ≤12mm 218 
resulted in a 6.5% major error rate.  219 
 220 
Plasmid structures and phylogenetic context of azithromycin resistant Shigella sonnei 221 
As observed previously, phylogenetic analyses confirmed that all genome-sequenced 222 
Vietnamese S. sonnei isolates belonged to the same clade of the Global III lineage (37). 223 
Investigation of the accessory genome confirmed that resistance to azithromycin within these 224 
S. sonnei isolates was mediated by either ermB or mphA in 16 of the sequenced isolates 225 
(Figure 3). Two of the 16 azithromycin-resistant isolates carried an ermB gene; the remaining 226 
14 carried an mphA gene. Notably, unlike the phenotypes of reduced susceptibility to 227 
fluoroquinolones and resistance against third generation cephalosporins (38), these 228 
azithromycin resistance genes were not restricted to individual sub-lineages or clonal 229 
expansions. Indeed, we estimated that between 2001 and 2008 ermB was acquired 230 
independently on at least two separate occasions, whilst mphA was acquired on at least five 231 
separate occasions, forming a small sub-clade of azithromycin-resistant organisms on two 232 
instances (Figure 3). However, these azithromycin resistance genes were transient and 233 
appeared not to be maintained within the population. 234 
 235 
Additional in silico analysis of the azithromycin resistance plasmids demonstrated that ermB 236 
was associated with two differing plasmid structures; S. sonnei 20094 harbored an IncFI 237 
plasmid (p20094) and S. sonnei EG430 carried an IncFII plasmid (pEG430-2). The IncFI 238 
plasmid (p20094) was assembled and found to be approximately 82kb in size, sharing 99% 239 
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 10 
DNA sequence identity with pEG356 (accession: FN594520.1), which we previously 240 
characterized in the Vietnamese S. sonnei isolate, EG356 (38). Similar to plasmid pEG356, 241 
p20094 carried a blaCTX-M-24 downstream of an ISEcp1. However, this replicon additionally 242 
contained an ISCR3 insertion sequence encompassing both the ermB and ermC genes. The 243 
IncFII plasmid pEG430-2 (accession LT174531.1) was 68,999bp and harbored ermB and 244 
ermC genes downstream of an IS6 transposase and had a 33,429bp DNA transfer region 245 
comprised of 37 contiguous genes (Figure 4a). Plasmid pEG430-2 shared significant DNA 246 
homology to other two other previously sequenced IncFII plasmids, p183660 (KX008967; 247 
coverage 86% and identity 98%) and pKSR100 (LN624486, coverage 89%, identity 98%), 248 
which were respectively identified in S. sonnei and S. flexneri 3a isolates associated with 249 
disease in MSM. 250 
  251 
Despite the erratic distribution of the mphA gene in the 2000 and 2010 S. sonnei isolates, 252 
sequence analysis demonstrated that these isolates likely carried mphA on a similar IncI 253 
plasmid backbone of a comparable size. A de novo assembly of S. sonnei DE105 effectively 254 
produced an entire plasmid sequence of 113,548bp, designated as pDE105 (accession 255 
number: MG569891) (Figure 4b). Plasmid pDE105 was analogous in size and structure to a 256 
previously described IncI plasmid pHV292 from an E. coli identified in the poultry 257 
production system in Switzerland (accession: KM377239.1). The mphA gene was located 258 
downstream of an IS3/IS911 transposase (orfA-orfB) and several additional AMR genes 259 
associated with a tnpA transposon and conferring resistance against sulphanomides (folP), 260 
streptomycin (strepAB), ß-lactams (bla-TEM-1), and tetracycline (tetA-tetR). Plasmid 261 
pDE105 also contained a type IV secretion system with traI/traJ genes responsible for 262 
conjugal transfer and an operon for pilus biosynthesis (pilI, pilQ, pilM, pilN, pilO, and pilP).  263 
 264 
We lastly performed plasmid isolation and sequencing on an additional S. sonnei isolate 265 
(DE891), which was distantly related to DE105. A de novo plasmid assembly produced seven 266 
contiguous sequences of 115kb spanning 99.6% of pDE105 and had 99% DNA sequence 267 
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 11 
identity. These data confirmed a common IncI plasmid backbone within the mphA positive 268 
Vietnamese S. sonnei. Mapping the remaining mphA plasmid sequences against pDE105, we 269 
found that they all shared a common genetic synteny (~90kb), which contained the same 270 
resistance gene cassettes. 271 
 272 
Discussion 273 
Azithromycin is a commonly though to be last resort drug for dysentery, but an increasing 274 
number of reports of decreased susceptibility against azithromycin in Shigella isolates is 275 
concerning. This problem has been observed in disparate populations including among MSM 276 
in affluent areas and children with dysentery in LMICs. Antimicrobial options for treating 277 
MDR and/or ciprofloxacin-resistant Shigella spp. are limited, especially for children or when 278 
an oral antimicrobial is required. In this large set of clinical Shigella spp. isolates collected 279 
over 18 years in Vietnam and Laos, both countries in which Shigella-associated dysentery in 280 
endemic, we found a low proportion (~5%) of Shigella isolates with decreased susceptibility 281 
to azithromycin. This low rate of non-susceptibility may be associated with the initial low 282 
rates of nalidixic acid and ciprofloxacin resistance and thus limited azithromycin usage. To 283 
our knowledge, this is the largest collection of Shigella spp. exhibiting decreased 284 
susceptibility against azithromycin reported from this region. Plasmid-mediated acquisition of 285 
mphA and ermB were identified as the principal mechanisms for azithromycin resistance.  286 
 287 
As human-restricted pathogens, Shigella spp. likely acquire resistance from the colonizing 288 
microbiota by plasmid transfer. This phenomenon has previously been demonstrated with E. 289 
coli donating mphA to S. sonnei (25). All of the identified mphA-associated plasmids have 290 
previously been described in E. coli, supporting their role as a reservoir from which AMR 291 
Shigella spp. may emerge. We demonstrate that the mechanism of azithromycin resistance to 292 
Shigella spp. arose sporadically during this period through at least seven plasmid acquisition 293 
events at different time points (from 2000 to 2009). Shigella spp. harboring azithromycin-294 
resistance plasmids appear not to have been maintained within the population, which may be 295 
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 12 
associated with a lack of antimicrobial selection pressure, heterogeneity in the populations 296 
sampled, or simply due to instability of the described resistance plasmids. There was only one 297 
example in the S. sonnei population in which an mphA-harboring plasmid sub-clade was 298 
maintained for at least two years (2000-2001).  299 
 300 
Given the limited antimicrobial treatment options available for Shigella-associated dysentery 301 
and the now widespread use of azithromycin, it is critical that laboratories can identify 302 
clinical isolates non-susceptible to azithromycin. We assessed the suitability of recently 303 
published ECVs for use as clinical susceptibility breakpoints. The MIC and disc zone sizes 304 
for S. flexneri in this study were consistent with the ECV guidance proposed by CLSI for 305 
MIC and disc diffusion measurements to identify non-wild type S. flexneri isolates, based on 306 
the detection of a resistance mechanism (16). In contrast, the distribution of MICs for 307 
azithromycin in S. sonnei were not concordant with the CLSI ECV guidance with a skew to 308 
the right. Our data support a higher ECV and susceptibility breakpoint for S. sonnei of 309 
≥32mg/L, and that a tentative zone size of ≤11mm around a 15µg azithromycin disc can 310 
identify non-wild type isolates. These thresholds are supported by confirmatory PCR 311 
amplifications and genome sequencing which corroborated the presence of azithromycin 312 
resistance gene in these 22 non-wild type isolates, and demonstrated an acceptably small 313 
proportion of discrepancies according to CLSI criteria (36). 314 
 315 
Limitations to our interpretations include the retrospective nature of the data analysis from the 316 
associated collection of organisms and a lack of clinical outcome data. The clinical impact of 317 
reductions in azithromycin susceptibility is uncertain, as azithromycin achieves a high 318 
concentration in intracellular compartments, such as within macrophages and colonic 319 
epithelial cells. The pathogenesis of Shigella spp. requires colonic epithelial cells for 320 
invasion, intracellular survival, and replication (8). Consequently a positive clinical outcome 321 
may be achieved even in the context of reduced in vitro susceptibility. Additionally, broth or 322 
agar dilution methods are the recognized standard method for MIC determination, and a 323 
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previous study has demonstrated potential issues with measuring disc diffusion and Etests to 324 
determine azithromycin susceptibility (39). In a small study, Jain et al. demonstrated a double 325 
zone phenomenon for both methods and reported that broth dilution MICs corresponded with 326 
values intermediate to inner and outer zones. While zone size interpretation may be a 327 
limitation, we additionally performed genotypic screening for associated resistance genes on 328 
all isolates, confirming our phenotypic testing results. Despite these limitations, the major 329 
strengths of our analyses include the large dataset of clinical isolates, the wide range of 330 
azithromycin MICs and the repeat testing of all isolates at a single center, thus limiting inter-331 
laboratory technical and interpretation errors. 332 
 333 
While azithromycin resistance among Shigella spp. causing dysentery and diarrhea was not 334 
common in the 18-year period between 1994 and 2012 in the sampled locations, the 335 
increasing proportion of MDR, fluoroquinolone and third generation cephalosporin resistant 336 
isolates will inevitably lead to the increasing use of azithromycin. During the sampling 337 
period, Shigella spp. with decreased susceptibility to azithromycin emerged on several 338 
separate occasions, but failed to become established in the population. Azithromycin is being 339 
increasingly used for the treatment of suspected and confirmed Shigella infections in LMICs, 340 
despite limited evidence. In this study we have developed tentative susceptibility breakpoints 341 
that we suggest should be evaluated in other locations. Correlation with proposed breakpoints 342 
and clinical outcomes in azithromycin-treated patients is a further priority. MIC and disc 343 
susceptibility breakpoints are urgently needed for the active global surveillance for 344 
azithromycin resistant strains of Shigella spp. Assessment of new alternative treatments are 345 
also required to stay ahead of this potential public health problem. 346 
 347 
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Table 1. Origin of Shigella isolates and frequency of selected resistance azithromycin markers 522 
Country/Study code Period 
Shigella species Antimicrobial resistance markers n/N (%) 
S. flexneri S. sonnei Other Total DSA NAL CRO MDR 
Vietnam/MS 1994-1998 58 22 0 80 3/70 (4.3) 1/80 (1.3) 0/80 (0) 57/80 (72.5) 
Vietnam/DE 2000-2002 42 62 8A 112 10/93 (10.8) 32/111 (28.8) 1/111 (0.9) 80/112 (71.4) 
Laos 2006-2012 35 9 1B 45 0/45 (0) 14/45 (31.1) 0/45 (0) 34/45 (75.6) 
Vietnam/EG 2007-2008 30 78 2C 110 4/104 (3.8) 75/108 (69.4) 22/108 (20.3) 96/110 (87.3) 
Vietnam/Huế 2008-2010 21 37 0 58 1/56 (1.8) 27/58 (46.6) 7/58 (12.0) 24/58 (41.4) 
Vietnam/AV 2009-2010 4 58 0 62 3/61 (4.9) 58/62 (93.5) 47/62 (75.8) 52/62 (83.9) 
Vietnam/KH 2009-2010 8 42 0 50 1/50 (2.0) 47/50 (94.0) 18/50 (36.0) 25/50 (50) 
Total  198 308 11 517 22/479 (4.8) 254/514 (49.4) 95/514 (18.5) 368/517 (71.2) 
 523 
DSA, decreased sensitivity to azithromycin (S. flexneri MIC≥16mg/L; S. sonnei MIC≥32mg/L) 524 
NAL, nalidixic acid (zone<19mm); CRO, ceftriaxone resistant organism (zone<23mm) 525 
MDR, multidrug resistant: intermediate or resistant to ≥3 classes of antimicrobials: penicillins (ampicillin), cephems (ceftriaxone), folate inhibitors 526 
(trimethoprim), phenicols (chloramphenicol), tetracyclines (tetracycline), quinolones (specifically nalidixic acid resistance), aminoglycosides (gentamicin) 527 
Study code, as per description in Reference 6.  528 
NA, not available; A 1 S. boydii, 1 S. dysenteriae, 6 NA; B 1 S. boydii; C 2 S. boydii. 529 
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 22 
 Table 2. Source, microbiological and genotypic characteristics of Shigella spp. isolates with decreased susceptibility to azithromycin 530 
Isolate ID Organism Year 
Age 
(years) 
Azithromycin susceptibility 
Resistance gene ESBL MDR 
MIC (mg/L) Zone (mm) 
MS025 S. flexneri 2a 1994-1998 0.75 32 11 mphA - + 
MS052 S. flexneri 1994-1998 0.83 16 14 mphA - + 
MS055 S. flexneri 6 1994-1998 0.92 512 6 mphA - + 
DE0088 S. sonnei 2000 4.00 512 6 mphA - + 
DE0105 S. sonnei 2000 1.50 512 6 mphA - + 
DE0108 S. sonnei 2000 1.50 512 6 mphA - + 
DE0185 S. sonnei 2000 0.67 512 6 mphA - + 
DE0199 S. sonnei 2000 2.42 512 6 mphA - + 
DE0490 S. sonnei 2000 1.67 512 6 mphA - + 
DE0579 S. sonnei 2001 4.00 512 6 mphA - + 
DE0885 S. sonnei 2001 3.00 512 6 mphA - + 
DE0891 S. sonnei 2001 1.50 128 6 mphA - + 
DE1336 S. sonnei 2002 1.92 512 6 mphA - + 
EG0094 S. sonnei 2007 2.58 256 6 mphA - + 
EG0352 S. sonnei 2007 2.50 256 6 mphA - + 
EG0419 S. flexneri 2a 2007 1.92 16 12 ermB - + 
EG0430 S. sonnei 2008 3.00 32 9 ermB + + 
Huế 49 S. flexneri 2009 4.00 128 6 mphA - + 
KH 39 S. flexneri 2009 0.75 16 12 mphA - + 
20094 S. sonnei 2010 1.42 32 9 ermB + + 
20343 S. sonnei 2010 1.58 512 6 mphA + + 
30295 S. sonnei 2010 1.75 512 6 mphA + + 
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Table 3. Discrepancy rates of false-susceptible and false-resistant isolates detected using 531 
proposed breakpoint criteria using an error rate-bounding method 532 
   Discrepancies N(%) 
Organism (breakpoint, g/L) MIC range
 
Number Very major Major 
S. flexneri (≤8) ≥R + 1 3 0 NA 
 R + S 4 0 1 (25) 
 ≤S + 1 191 NA 5 (2.6) 
 Total 198 0 6 (3.0) 
     
S. sonnei (≤16) ≥R + 1 14 0 NA 
 R + S 2 0 0 
 ≤S + 1 292 NA 3 (1.0) 
 Total 308 0 3 (1.0) 
 533 
R, non-susceptible MIC; S, susceptible MIC; NA, not applicable  534 
 o
n
 February 12, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://aac.asm
.org/
D
ow
nloaded from
 
 24 
Figure 1. The distribution of azithromycin MICs for S. flexneri and S. sonnei in Southeast 535 
Asia 536 
Histograms showing the number of S. sonnei (green) and S. flexneri (blue) collected in 7 537 
studies performed in Southeast Asia between 1994 and 2012 exhibiting different MICs 538 
against azithromycin (mg/L).  539 
 540 
Figure 2. The relationship between azithromycin MIC and inhibition zone size in Southeast 541 
Asian Shigella spp. 542 
Plots showing the relationship between inhibition zone size (mm, x-axis) and MIC (mg/L, y-543 
axis) for azithromycin in S. flexneri (blue, left) and S. sonnei (green, right). The squares are 544 
colored with respect to the number of isolates in each group, the number of isolate in each 545 
group is additionally provided. 546 
  547 
Figure 3. Phylogenetic tree of S. sonnei in Southeast Asia  548 
Phylogenetic tree of 261 S. sonnei genomes (global lineage III) and an additional 54 genomes 549 
of isolates collected during the same period (1995-2011). Tree constructed through 2,812 550 
chromosomal SNPs. Phylogenetic reconstruction was performed using multiple alignments of 551 
SNPs by maximum-likelihood based phylogenetic inference and displayed and annotated 552 
using iTOL. The year/period of isolation is highlighted in the outer ring and the organisms 553 
with reduced susceptibility against azithromycin; mphA positive isolates are highlighted in red 554 
and ermB positive isolates are highlighted in blue.  555 
 556 
Figure 4. Maps of azithromycin S. sonnei azithromycin resistant plasmids pDE105 and 557 
pEG403_2 558 
Maps of A) pDE105 and B) pEG403_2 azithromycin resistance plasmids isolated from 559 
Vietnamese S. sonnei. The coding sequences of are number consecutively and notable 560 
genes/regions are highlighted, which include DNA transfer regions, replication, antimicrobial 561 
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resistance, and the azithromycin resistance genes (ermB and mphA, respectively). The size 562 
(bp) of each plasmid are shown in the center. 563 
 564 
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